Type 2 Diabetes

Let’s start off with what is in the pipeline.

Early initiation of therapy hoped to reduce long-term morbidity, mortality by getting to goal earlier; potentially alter the natural history of the disease.

Adults with type 2 diabetes and microvascular complications have an increased risk for severe periodontitis compared with those without microvascular complications.

Survey estimates that diabetes accounts for many more deaths in the United States than are being reported on death certificates — and that diabetes is actually the third leading cause of death.

Phase-3 study to evaluate efficacy and safety of ertugliflozin monotherapy.

Study shows significant improvement in diabetes control with a 1 point drop in A1c with less hypoglycemia.

FDA label update will increase drug use in persons with historical contraindications or precautions.

Using fibrates to treat hypertriglyceridemia has not shown significant benefit in cardiovascular mortality in previous studies.

U.S. researchers confirm that prediabetes risk, presence can be identified using A1C test with same accuracy as other, less convenient tests.

Object of meta-analysis to assess diagnostic accuracy of screening tests for prediabetes and efficacy of interventions (lifestyle or metformin) in preventing diabetes.